SCHEMBL9974724

SCHEMBL9974724

COC(=O)c1ccc(C)c(-c2ccc3c(=O)n(Cc4ccc(OC)cc4)ccc3c2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 3/20 0.47
HDAC6 Q9UBN7 3/20 0.47
HDAC11 Q96DB2 2/20 0.47
HDAC3 O15379 2/20 0.46
HDAC1 Q13547 2/20 0.46
HDAC2 Q92769 2/20 0.46
HDAC10 Q969S8 2/20 0.46
HDAC4 P56524 1/20 0.46
HDAC7 Q8WUI4 1/20 0.46
HDAC9 Q9UKV0 1/20 0.46
HDAC5 Q9UQL6 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
LMNA P02545 6/20 0.46
MAPT P10636 3/20 0.45
POLB P06746 2/20 0.45
ROCK2 O75116 1/20 0.44
ROCK1 Q13464 1/20 0.44
TP53 P04637 4/20 0.43
RXFP1 Q9HBX9 2/20 0.43
ALDH1A1 P00352 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2417694 0.91 LMNA (0.46) HDAC8HDAC6HDAC11HDAC3HDAC1
SCHEMBL12284336 0.91 MAPK8 (0.43) HDAC8HDAC6HDAC11HDAC3HDAC1
SCHEMBL9974723 0.91 LMNA (0.41) HDAC8HDAC6HDAC11HDAC3HDAC1
SCHEMBL9974659 0.90 P2RX7 (0.47) LMNAPOLBROCK2ROCK1ALDH1A1
SCHEMBL9974663 0.88 PTGS2 (0.45) LMNAPOLBROCK2ROCK1ALDH1A1
SCHEMBL2416054 0.87 MAPK14 (0.56) ALDH1A1
SCHEMBL9974704 0.85 MAPK14 (0.46) LMNAMAPTTP53ALDH1A1
SCHEMBL2422151 0.84 MAPK14 (0.51)
SCHEMBL2419000 0.82 LMNA (0.39) LMNAMAPTPOLBTP53ALDH1A1
SCHEMBL2419798 0.80 GRIK1 (0.44) LMNAROCK2ROCK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144881-B1 ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA ASTRAZENECA AB (SE) 2012-06-20 EP disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008122765-A1 NEW COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 CYP3A7, UGT1A7, UGT2B7 HDAC8 1085/4885HDAC6 177/4885HDAC11 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.